1214249-92-9

Upstream product

• 1433989-98-0 (1-benzyl-4-(phenylsulfonyl)piperazine-2,6-diyl)dimethanol 
• 864448-25-9 (S)-ethyl 2-bromo-3-(N-((R)-2-bromo-3-ethoxy-3-oxopropyl)phenyl-sulfonamido)propanoate 
• 938-05-6 dibromamine-B 
• 98-10-2 benzenesulfonamide 
• 335620-96-7 9-benzyl-3-(phenylsulfonyl)-7-oxa-3,9-diaza-bicyclo[3.3.1]nonane 

Downstream Products

• 1214249-93-0 9-methyl-3-(phenylsulfonyl)-7-oxa-3,9-diaza-bicyclo[3.3.1]nonane 

Relevant academic research and scientific papers

ALKYLATED PIPERAZINE COMPOUNDS

Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

6-SUBSTITUTED BENZOXAZINES

The present invention is concerned with 6-substituted benzoxazine derivatives of formula (I) wherein X, Y, R1 and R2 are as described herein, their manufacture, and pharmaceutical compositions containing them. The active compounds of the present invention are 5-HT5A receptor antagonists, useful in the prevention and/or treatment of depression, anxiety disorders, schizophrenia, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, pain, memory disorders, dementia, disorders of eating behaviors, sexual dysfunction, sleep disorders, abuse of drugs, motor disorders, Parkinson's disease, psychiatric disorders or gastrointestinal disorders.